Equities
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and improve people's lives. It operates in human therapeutics segment. The Company’s marketed products portfolio includes Aranesp, ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine), KYPROLIS (carfilzomib), Maridebart cafraglutide, (infliximab-axxq), Evenity, LumaKras, Nplate and XGeva, others.

  • Revenue in USD (TTM)28.19bn
  • Net income in USD6.72bn
  • Incorporated1986
  • Employees26.70k
  • Location
    Amgen IncOne Amgen Center DriveTHOUSAND OAKS 91320United StatesUSA
  • Phone+1 (805) 447-1000
  • Fax+1 (805) 447-1010
  • Websitehttps://www.amgen.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Zoetis Inc8.54bn2.34bn78.15bn14.10k33.6615.6627.619.155.075.0718.4810.900.5851.036.78605,957.4016.0214.4719.3717.1870.4769.8027.3925.772.0017.150.568226.895.747.9610.8811.1316.7124.37
Gilead Sciences, Inc.27.12bn5.66bn91.27bn18.00k16.264.0010.993.374.504.5021.5618.330.43283.955.751,506,445.008.966.7410.918.1276.0478.6420.6916.951.277.630.523481.22-0.60484.1523.370.7436-8.745.64
Bristol-Myers Squibb Co45.01bn8.03bn104.33bn34.10k13.373.545.862.323.863.8621.6614.560.46894.245.011,319,824.008.383.0510.893.7676.4476.1317.867.691.3112.390.5743133.63-2.5014.8126.8410.034.927.34
Regeneron Pharmaceuticals Inc13.12bn3.95bn105.36bn13.45k27.614.0424.098.0334.7634.76115.32237.410.42110.72892.39975,256.5012.6920.1814.1923.2286.1686.6330.1438.114.94--0.0943--7.7614.34-8.8710.7219.32--
Vertex Pharmaceuticals Incorporated9.87bn3.62bn106.26bn5.40k29.616.0327.9610.7713.8913.8937.8868.220.48282.106.571,827,630.0017.7119.9220.9323.6487.2187.6736.6835.853.78--0.0210.0010.5126.498.9646.5022.02--
Amgen Inc28.19bn6.72bn145.18bn26.70k21.6923.2713.465.1512.4912.4952.4211.640.34741.164.391,055,805.008.2810.3610.4813.0670.1675.4123.8326.511.133.150.91259.547.093.492.52-4.368.5410.04
Pfizer Inc58.50bn2.13bn156.97bn88.00k77.161.7618.552.680.35930.356610.2915.770.27611.885.29664,738.601.038.201.3010.4069.2469.343.7122.680.6935--0.44660.11-41.707.46-93.20-7.9412.213.82
Data as of Mar 18 2024. Currency figures normalised to Amgen Inc's reporting currency: US Dollar USD

Institutional shareholders

31.40%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 Dec 202346.65m8.71%
SSgA Funds Management, Inc.as of 31 Dec 202329.46m5.50%
BlackRock Fund Advisorsas of 31 Dec 202328.41m5.30%
PRIMECAP Management Co.as of 31 Dec 202314.59m2.72%
Geode Capital Management LLCas of 31 Dec 202312.34m2.30%
Charles Schwab Investment Management, Inc.as of 31 Dec 202310.39m1.94%
Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Dec 20237.93m1.48%
Capital Research & Management Co. (Global Investors)as of 31 Dec 20236.71m1.25%
Northern Trust Investments, Inc.(Investment Management)as of 31 Dec 20235.96m1.11%
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Dec 20235.84m1.09%
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.